IP Verse

Variant Immunoglobulins With Improved Manufacturability - EP2467400

The patent EP2467400 was granted to Lonza Biologics on Jan 24, 2018. The application was originally filed on Aug 20, 2010 under application number EP10749484A. The patent is currently recorded with a legal status of "Revoked".

EP2467400

LONZA BIOLOGICS
Application Number
EP10749484A
Filing Date
Aug 20, 2010
Status
Revoked
Jul 3, 2020
Grant Date
Jan 24, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANOct 24, 2018VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB -
WHITEOct 24, 2018BOULT WADE TENNANT -

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO1992US09965-
DESCRIPTIONEP0120694
DESCRIPTIONEP0125023
DESCRIPTIONEP0184187
DESCRIPTIONEP0239400
DESCRIPTIONGB2188638
DESCRIPTIONWO9201047
DESCRIPTIONWO9413804
INTERNATIONAL-SEARCH-REPORTUS2005244403
INTERNATIONAL-SEARCH-REPORTWO03074679
INTERNATIONAL-SEARCH-REPORTWO2005045442
INTERNATIONAL-SEARCH-REPORTWO2009155513
OPPOSITIONEP2196541
OPPOSITIONUS2005003347
OPPOSITIONUS6936706
OPPOSITIONUS7575893
OPPOSITIONWO2004065417
OPPOSITIONWO2004101738
OPPOSITIONWO2005044859
OPPOSITIONWO2006074071
OPPOSITIONWO2006083971
OPPOSITIONWO2006084264
OPPOSITIONWO2009041062
OPPOSITIONWO2011021009

Non-Patent Literature (NPL) Citations (48) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BAGSHAWE K.D. ET AL., ANTIBODY, IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, (1991), vol. 4, pages 915 - 922-
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426-
DESCRIPTION- CARPENTER ET AL., J PHARM SCI., (2009), vol. 98, no. 4, pages 1201 - 5-
DESCRIPTION- DEMEULE, B ET AL., INT J PHARM, (2007), vol. 329, pages 37 - 45-
DESCRIPTION- DEMEULE, B ET AL., MABS, (2009), vol. 1, no. 2, pages 142 - 150-
DESCRIPTION- GABRIELSON JP ET AL., J PHARM SCI, (2007), vol. 96, no. 2, pages 268 - 79-
DESCRIPTION- HAWE, A. ET AL., PHARMACEUTICAL RESEARCH, (2008), vol. 25, no. 7, pages 1487 - 99-
DESCRIPTION- HAWE, A.; SUTTER, M; JISKOOT, W., PHARMACEUTICAL RESEARCH, (2008), vol. 25, no. 7, pages 1487 - 99-
DESCRIPTION- HUSTON ET AL., PNAS USA, (1988), vol. 85, pages 5879 - 5883-
DESCRIPTION- KIESE S ET AL., J PHARM SCI, (2008), vol. 97, no. 10, pages 4347 - 66-
DESCRIPTION- KNAPPIK ET AL., J. MOL. BIOL., (2000), vol. 296, pages 57 - 86-
DESCRIPTION- KREBS ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (2001), vol. 254, pages 67 - 84-
DESCRIPTION- LEDERMANN J.A. ET AL., INT J. CANCER, (1991), vol. 47, pages 659 - 664-
DESCRIPTION- LIU J, AAPS J, (2006), vol. 8, pages 580 - 9-
DESCRIPTION- Methods for structural analysis of protein pharmaceuticals, AAPS PRESS, (2005), pages 661 - 6-
DESCRIPTION- PADLAN ET AL., MOL IMMUNOL., (1991), vol. 28, pages 489 - 498-
DESCRIPTION- P. HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448-
DESCRIPTION- PLüCKTHUN, A., BIOLTECHNOLOGY, (1991), vol. 9, pages 545 - 551-
DESCRIPTION- QUEEN ET AL., PNAS USA, (1989), vol. 86, pages 10029 - 10033-
DESCRIPTION- REF, M.E., CURR. OPINION BIOTECH., (1993), vol. 4, pages 573 - 576-
DESCRIPTION- RIECHMAN ET AL., NATURE, (1988), vol. 332, pages 323 - 327-
DESCRIPTION- S. HU ET AL., CANCER RES., (1996), vol. 56, pages 3055 - 3061-
DESCRIPTION- TANHA ET AL., PROTEIN ENG DES SEL., (200611), vol. 19, no. 11, pages 503 - 9-
DESCRIPTION- TRILL J.J. ET AL., CURR. OPINION BIOTECH, (1995), vol. 6, pages 553 - 560-
DESCRIPTION- WARD, E.S. ET AL., NATURE, (1989), vol. 341, pages 544 - 546-
DESCRIPTION- Y. REITER ET AL., NATURE BIOTECH, (1996), vol. 14, pages 1239 - 1245-
DESCRIPTION- HONEGGER, A; PLüCKTHUN A., "Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modelling and Analysis Tool", J. MOL. BIOL, (2001), vol. 309, doi:doi:10.1006/jmbi.2001.4662, pages 657 - 670, XP004626893
EXAMINATION- WINKLER K ET AL, "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20001015), vol. 165, no. 8, ISSN 0022-1767, pages 4505 - 4514, XP002579393-
EXAMINATION- Ellen Hsu, "The variation in immunoglobulin heavy chain constant regions in evolution", Seminars in Immunology, (19940101), vol. 6, pages 383 - 391, XP055264026
EXAMINATION- EWERT S ET AL, "Biophysical Properties of Human Antibody Variable Domains", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 325, no. 3, doi:10.1016/S0022-2836(02)01237-8, ISSN 0022-2836, (20030117), pages 531 - 553, (20030117), XP027180832
EXAMINATION- Frank W Putnam ET AL, "Amino acid sequence of the first constant domain and the hinge region of the delta heavy chain of human IgD", Proc. Natl. Acad. Sci. USA, (19811001), vol. 78, no. 10, pages 6168 - 6172, XP055264080
EXAMINATION- RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436
INTERNATIONAL-SEARCH-REPORT- MONSELLIER E ET AL, "Improving the Stability of an Antibody Variable Fragment by a Combination of Knowledge-based Approaches: Validation and Mechanisms", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 362, no. 3, doi:DOI:10.1016/J.JMB.2006.07.044, ISSN 0022-2836, (20060922), pages 580 - 593, (20060922), XP024951393 [X] 1-4,27,52,53,57 * the whole document * [Y] 5-26,29-47,49,50,55,56
INTERNATIONAL-SEARCH-REPORT- CHENNAMSETTY N ET AL, "Aggregation-Prone Motifs in Human Immunoglobulin G", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 391, no. 2, ISSN 0022-2836, (20090814), pages 404 - 413, (20090613), XP026350710 [X] 1,2 * the whole document * [Y] 5-26,29-47,49,50,55,56
INTERNATIONAL-SEARCH-REPORT- MCDONAGH C F ET AL, "Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, (20030725), vol. 14, no. 5, doi:DOI:10.1021/BC0340316, ISSN 1043-1802, pages 860 - 869, XP002378783 [X] 2-6,27,52,53,57 * the whole document * [Y] 5-26,29-47,49,50,55,56
INTERNATIONAL-SEARCH-REPORT- CHENNAMSETTY NARESH ET AL, "Design of therapeutic proteins with enhanced stability", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 106, no. 29, doi:DOI:10.1073/PNAS.0904191106, ISSN 0027-8424, (20090721), pages 11937 - 11942, (20090701), XP002546638 [X] 1,2,48,52,53,57 * the whole document * [Y] 5-26,29-47,49,50,55,56
INTERNATIONAL-SEARCH-REPORT- KIPRIYANOV S ET AL, "Two amino acid mutations in an anti-human CD3 single-chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, (19970401), vol. 4, no. 10, doi:DOI:10.1093/PROTEIN/10.4.445, ISSN 0269-2139, pages 445 - 453, XP002079905 [X] 2-4,27,28 * the whole document * [Y] 5-26,29-47,49,50,55,56
INTERNATIONAL-SEARCH-REPORT- KÜGLER MARKUS ET AL, "Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS MAR 2009, (20090301), vol. 22, no. 3, doi:DOI:10.1093/PROTEIN/GZN079, pages 135 - 147, XP002575212 [X] 2,3,52,57 * the whole document * [Y] 5-26,29-47,49,50,55,56
OPPOSITION- WANG et al., "Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: A computational analysis", Pharm Res, (20100427), vol. 27, no. 8, pages 1512 - 1529, XP019827983-
OPPOSITION- EWERT et al., "Biophysical properties of human antibody variable domains", J. Mol. Biol., (20030000), vol. 325, pages 531 - 553, XP002343836
OPPOSITION- MULLER et al., "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4.A resolution and mutational analysis of the interface", Structure, (19980000), vol. 6, pages 1153 - 1167, XP002986094
OPPOSITION- SEUNG-WOOK CHI et al., "Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism", PNAS, (20070000), vol. 104, no. 22, pages 9230 - 9235, XP055527254
OPPOSITION- CHENNAMSETTY et al., "Design of therapeutic proteins with enhanced stability", PNAS, (20090721), vol. 106, no. 29, pages 11937 - 11942, XP002546638
OPPOSITION- CHENNAMSETTY et al., "Design of therapeutic proteins with enhanced stability", Proc. Nat. Acad. Sci., U.S.A., (20090000), vol. 106, no. 29, pages 11937 - 11942, XP002546638
OPPOSITION- VERBEKE et al., "Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor", Journal of Thrombosis and Haemostasis, (20040000), vol. 2, no. 2, pages 289 - 297, XP055082582
OPPOSITION- BEDOUELLE et al., "Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus", FEBS Journal, (20050000), vol. 273, pages 34 - 46, XP055183465
OPPOSITION- ZWICK et al., "The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5", J Virol, Vol., (20040000), vol. 78, no. 6, pages 3155 - 3161, XP008125658
OPPOSITION- WANG et al., "Potential aggregation prone regions in biotherapeutics", mAbs, (20090500), vol. 1, no. 3, pages 254 - 267, XP055410727

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents